1Pharmacopsychiatry 2011 Jan 44: 15-20
PMID20821366
TitleAssociation study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia.
AbstractMarked inter-individual variation has been observed with respect to the risk of weight gain and related metabolic disturbances during antipsychotic treatment, which in part could be explained by heritability. Such adverse effects have been proposed to occur through drug-induced mechanisms involving both the central nervous system and different peripheral tissues.
We genotyped tagSNPs in several genes ( ADIPOQ, PRKAA1, PRKAA2, PRKAB1, PRKAG1, PRKAG2, PRKAG3, FTO and FABP3) that regulate lipid and energy homeostasis for their possible association to antipsychotic-induced weight gain.
In a sample of 160 patients of German origin with schizophrenia who had been monitored with respect to body weight, we found marked association between antipsychotic-related changes in BMI and 6 markers in the adiponectin gene ( ADIPOQ).
These findings support previous observations (in patients' serum) that adiponectin is involved in antipsychotic-mediated metabolic adverse effects.
SCZ Keywordsschizophrenia
2J Psychiatr Res 2012 Apr 46: 462-8
PMID22305490
TitleAssociation study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain.
AbstractWeight gain and metabolic syndrome are the most common deleterious side effects following treatment with second generation antipsychotic drugs such as clozapine and olanzapine. However, the mechanisms underlying these negative effects of second generation antipsychotic drugs are not fully understood. In this study we investigate whether variants in the genes coding for the ?-catalytic (PRKAA1, PRAKAA2) and the ? regulatory subunits (PRKAB1 and PRKAB2) of the cellular energy sensor AMP-activated protein kinase (AMPK) are associated with antipsychotic-induced weight gain. To accomplish this, ten polymorphisms in 208 schizophrenia or schizoaffective disorder patients treated with clozapine, haloperidol, risperidone or olanzapine for up to 14 weeks were analyzed. Significant association was observed between rs3766522 in PRKAB2 (AA vs. AT+TT; p=0.022) and rs10789038 in PRKAA2 (GG+GA vs. AA, p=0.023) with weight change (%) in patients of European ancestry following treatment with clozapine or olanzapine. Allelic association of the T-allele of rs3766522 (p=0.019) and the G-allele of rs10789038 (p=0.041) with weight change (%) was also observed. Analysis of raw weight gain revealed that carriers of the T-allele of rs3766522 (AT+TT, 4.3kg3.7) gained more weight than the AA-genotype carriers (2.5kg4.5, p=0.042). Similarly, carriers of the G-allele of rs10789038 (GG+GA, 4.2kg4.5) gained more weight than AA-homozygotes (1.5kg2.9, p=0.014) under antipsychotic treatment. In conclusion, we observed significant associations between polymorphisms in AMPK subunit genes and weight gain induced by clozapine and olanzapine.
SCZ Keywordsschizophrenia